(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (PINKSHEETS: PGCX) PanGenex Corp., (OTCBB: MSBT) MedaSorb Technologies Corp., (NASDAQ: ACOR) Acorda Therapeutics, Inc. (NASDAQ: ADCT) ADC Telecommunications, Inc., (NASDAQ: ADES) ADA-ES, Inc., www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: PGCX - PanGenex Corp.) LATEST NEWS!! PanGenex Forms Exclusive Strategic Partnership with BulovaTech Labs To Jointly Develop & Commercialize Patented Nutraceuticals TAMPA, Fla., Nov 16, 2009 -- PanGenex Corporation (Pink Sheets: PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., ("LABS"), a wholly-owned subsidiary of Bulova Technologies Group Inc., (Pink Sheets: BLVT). The new partnership supports the joint development and commercialization of PanGenex's nutraceutical and healthcare products. The partnership includes an exclusive collaboration agreement that will accelerate the development of proprietary technologies and products, which will be marketed by PanGenex under the PanGenex trademark.

"BulovaTech Labs is an ideal partner for PanGenex," said Jim Mosbaugh, COO of PanGenex. "Through LABS' parent company, Bulova Technologies Group, LABS has access to substantial technical and financial resources. Together, we can continue to drive momentum for sales of unique, condition-specific, and proven effective nutraceutical and healthcare products worldwide." PanGenex has developed unique patent-protected products, which effectively address cardiac health, soft tissue calcification, and blood lipids. PanGenex's trademarked and patented products include: Calci-Clear (TM), LIPIDEME (TM) and Omeganol (TM), all of which are showing strong physician and end user acceptance in the $538 Billion soft tissue calcification treatment market. "LABS is an exciting venture that seeks to invest in high-growth ground floor opportunities, including the rapidly growing market for nutraceuticals. We are confident that by collaborating with PanGenex we can rapidly bring successful commercial products to markets worldwide," stated BulovaTech Chairman John Stanton.

About BulovaTech Labs, Inc.

BulovaTech Labs, Inc. ("LABS"), a wholly-owned subsidiary of Bulova Technologies Group, Inc. (Pink Sheets: BLVT), was founded in 2009 with the purpose to incubate, capitalize on, secure, and expand the market potential for proven market-ready technologies and products in the nutraceutical and health related industries. For more information, please visit http://www.bulovatechgroup.com.

About PanGenex Corporation PanGenex pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription.

Pursuant to FDA regulations, since 2006, PanGenex has voluntarily submitted its product labels for review without incidence. PanGenex products are currently sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: MSBT - MedaSorb Technologies Corp.) LATEST NEWS!! MedaSorb Technologies Corporation Provides Clinical Update MONMOUTH JUNCTION, NJ, Nov 13, 2009 -- MedaSorb Technologies Corporation (OTCBB: MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., provided an update of its clinical program.

Dr. Phillip Chan, Chief Executive Officer, stated, "As we welcome many new investors to the company, I wanted to give a brief update on our European Sepsis Trial. As many know, MedaSorb has developed a powerful blood purification technology platform that can remove drugs, proteins, toxins and other substances from blood and physiologic fluids. With our flagship product CytoSorb(TM), we are currently conducting one of the largest randomized, controlled clinical trials of its kind to treat patients with severe sepsis and respiratory failure by directly attempting to reduce 'cytokine storm' that often leads to organ failure and death in this disease. Severe sepsis and cytokine storm are particularly relevant today, as they have likely contributed to the deaths of many people infected with the H1N1 swine influenza virus in countries across the world. By potentially reducing these toxic cytokine levels in the blood, we hope CytoSorb(TM) can prevent and limit organ injury, giving patients time to heal and recover." Preliminary Clinical Data from Sepsis Pilot Study -- We previously discussed that the first 22 patients in our European Sepsis Trial were categorized into a pilot study. Treatment was well-tolerated in this study and there were no serious device related adverse events. We currently have fully-monitored, completed data sets on 13 of these patients. These represent all twelve patients from a major, well-known, academic university hospital as well as one patient from another large clinical trial site. Seven of these patients were treated with CytoSorb(TM) and standard of care therapy, while six others were in the control group receiving standard of care therapy alone. We are encouraged that an analysis of the data demonstrates improvements in many of the secondary and exploratory endpoints of the trial in the treatment group compared to the control group including: -- 28-day and 60-day all cause mortality -- Ventilator free days -- Pace of ventilator weaning -- Organ failure scores -- Vasopressor use -- Days in the intensive care unit These objective endpoints in the treatment of severe sepsis are important. First, improvements in these key outcomes are difficult to accomplish but are directly associated with improved patient outcome and survival. Secondly, these are parameters used by critical care physicians to judge how patients are doing and are predictors of length of stay and cost of stay in the intensive care unit. Lastly, improvements in these criteria are consistent with how CytoSorb(TM) is intended to work. Cytokine storm-induced organ failure such as acute respiratory distress syndrome requiring mechanical ventilation, hemodynamic shock requiring vasopressors, and renal failure requiring dialysis is well-documented. Reduction of cytokine storm by CytoSorb(TM) is intended to reduce organ failure and the need for these types of interventions and we are pleased to see this correlation.

European Sepsis Trial -- Including our Sepsis Pilot Study, we have enrolled a total of 39 patients in our trial, including 17 patients under a new protocol designed to improve data quality and enhance recruitment. To complete our trial, we are looking to enroll an additional 40 patients, but if needed, can go up to 60. We have increased the number of participating trial sites to 12 and are currently leveraging our existing hospital network to include several additional medical intensive care units. This should benefit our enrollment by increasing the number of patient candidates that can participate in our trial. In addition, we are entering what is expected to be a busy flu and pneumonia season, which are major causes of severe sepsis. With a successful completion of our trial, we continue to anticipate CE Mark approval and potential for initial commercial sales of our device in Europe in 2010. We are currently working in parallel to prepare our CE Mark application which will be finalized once our trial is successfully completed.

"We continue to press forward with other potential clinical applications of our blood purification technology," said Dr. Chan. "For example, the U.S. government has now declared the current H1N1 influenza pandemic a national public health emergency, enabling the FDA to provide Emergency Use Authorization (EUA) of drugs, devices, diagnostic tests, and biological products that have not yet been approved, cleared or licensed by the FDA. This, as well as the increased attention to H1N1 influenza by government funding agencies, opens up a number of opportunities for us that we are actively pursuing for our CytoSorb(TM) device. The link between cytokine storm, mortality and highly virulent strains of influenza like H5N1 avian flu, 1918 H1N1 Spanish Influenza, as well as other respiratory viruses like SARS coronavirus can be found in a number of non-company publications included towards the end of our publication list, http://www.cytosorbents.com/pdf/CytoSorbents_Publications_11_2009_final.pdf . There remains a significant unmet medical need for treatment of critically-ill influenza patients who have failed protection of vaccines and early treatment with anti-viral therapies." Dr. Chan concluded, "In summary, we are pleased to see a potential clinical benefit of CytoSorb(TM) in a relatively small number of patients in our Sepsis Pilot Study, but recognize this was a small data set of 13 patients and would caution investors to avoid extrapolating these results to the larger trial which is still underway. We believe 2010 will be a pivotal year for the company as we hope to complete our European Sepsis Trial successfully and transition from a development stage to a commercial stage company. We have a number of interesting opportunities ahead of us and we thank our shareholders for their continued support." About MedaSorb, CytoSorbents and CytoSorb(TM) MedaSorb Technologies Corporation, and its operating subsidiary CytoSorbents, is a therapeutic device company in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb(TM). Severe sepsis is typically caused by bacterial infections like pneumonia, or viral infections like influenza. It afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Much of the organ failure and mortality in severe sepsis is caused by the abnormal massive production of cytokines by the immune system, often called "cytokine storm." CytoSorb(TM) is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped through the CytoSorb(TM) cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb(TM) in the European Union. CytoSorb(TM) is one of a number of different resins designed for different medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, treatment of rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company's website: www.cytosorbents.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: ACOR - Acorda Therapeutics, Inc.) LATEST NEWS!! Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference HAWTHORNE, N.Y., Nov 16, 2009 -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 3:10 p.m. ET at the St. Regis Hotel in New York, NY.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Acorda Investor Relations section of the website at www.acorda.com, or you may use the link: http://www.wsw.com/webcast/lz6/acor/.

Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection. An archived version of the webcast will be available until February 17, 2010 on the Acorda website in the Investor Relations section; to access please use the link http://phoenix.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-irhome.

About Acorda Therapeutics Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: ADCT - ADC Telecommunications, Inc.) LATEST NEWS!! ADC's FlexWave Prism Enables 4G Wireless Services at Michigan State FlexWave System Designed to Enable Easy Transition from 2G/3G Services to LTE MINNEAPOLIS, Nov 16, 2009 --Outdoor DAS Products Offer Cost-effective Coverage and Capacity at 5,200-Acre Campus with More Than 46,000 Students --On-campus Service Providers Use ADC DAS for Wireless Service Enhancements ADC (NASDAQ: ADCT) (www.adc.com) today announced that its FlexWave Prism(TM) outdoor distributed antenna system (DAS) has been deployed at Michigan State University (MSU) to support current mobile voice and data traffic and enable an easy transition to LTE services support.

MSU's 5,200-acre campus is one of the largest in the United States. Its 553 buildings host tens of thousands of people on a typical day and many more during events at the 75,005-seat Spartan Stadium. Macro cell towers surround the edges of the campus but do not provide adequate service for the dense user population, nor do they penetrate campus facilities effectively. Since 2004, service providers enhancing their on-campus services at MSU have chosen ADC's outdoor DAS products to do so -- including MetroPCS, Sprint, Nextel and Verizon. This latest upgrade was done by Verizon Wireless, which replaced existing ADC LRCS products with FlexWave Prism. Prism accommodates multiple frequency bands or service providers and supports LTE upgrades in a single system. As with MSU's previous DAS deployments, this latest project leverages a 60-mile existing fiber optic network owned by the university.

"Outdoor DAS is really the most efficient way to cover buildings and outdoor spaces at a large and densely-populated campus like ours," said Jeff Carpenter, planning and engineering supervisor for telecommunication systems at Michigan State University. "We like DAS because the products use a small amount of fiber, so we don't have to allocate a lot of dark fiber resources, and their electronics are also small and low-power, so we can easily accommodate discrete systems from multiple carriers in our limited equipment rooms. We've really seen a drop in service complaints as each carrier's system has been installed." The recent FlexWave Prism deployment includes 15 mast- and building-mounted DAS remote units. The compact and low-power consuming remote units are deployed in rooftop mechanical equipment spaces on each building.

"With the ability to cover up to four sectors with a single, compact antenna unit, FlexWave Prism is ideal for delivering high-bandwidth coverage to complex environments like the Michigan State campus," said Tony LeFebvre, director of product management for outdoor DAS products for ADC. "Service providers like Verizon are now realizing that Prism's multi-band, multi-protocol flexibility also enables an easy transition to 4G services because they can simply plug a new module into an existing system and through software adjust the digital simulcast configuration to adapt to changing user patterns." About ADC Network Solutions ADC's Network Solutions Business Unit offers products that deliver high-performance wireless coverage and capacity to business and consumer subscribers in any indoor or outdoor location. ADC is the global leader in advanced in-building wireless solutions and compact network systems, and is a leader in solutions that enhance coverage in macro networks.

About ADC ADC provides the connections for wireline, wireless, cable, broadcast, and enterprise networks around the world. ADC's innovative network infrastructure equipment and professional services enable high-speed Internet, data, video, and voice services to residential, business and mobile subscribers. ADC (NASDAQ: ADCT) has sales into more than 130 countries. Learn more about ADC at www.adc.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: ADES - ADA-ES, Inc.) LATEST NEWS!! ITTLETON, Colo., Nov 16, 2009 -- ADA-ES, Inc. (NASDAQ:ADES) today announced financial results for the third quarter ended September 30, 2009.

Overview of Third Quarter Results For the third quarter, total revenues were $3.7 million compared to $5.0 million in the third quarter of 2008. The Company experienced a $1.5 million decline in Mercury Emission Control ("MEC") sales, primarily due to lower Activated Carbon Injection ("ACI") system sales as a result of industry uncertainty surrounding the likely timing of Federal mercury regulation. The Company expects MEC revenues to remain at approximately this level for the next few quarters until Federal mercury control legislation is enacted or regulations are promulgated.

In the third quarter, gross margin was 32%, as compared to 33% in the prior year period. General and administrative expenses increased substantially to $7.9 million from $3.5 million in the second quarter of 2009, and compared to $1.6 million in the third quarter of last year, due to legal expenses associated with ongoing litigation. The Company expects legal costs to decline in the fourth quarter of 2009.

Due in large part to the aforementioned legal expenses, the Company reported an operating loss of $7.0 million compared to an operating loss of $256,000 in the third quarter of 2008, and a net loss of $5.3 million, or $0.76 per diluted share, compared to a net loss of $167,000, or $0.03 per diluted share, in the 2008 third quarter.

Industry Update & Outlook Dr. Michael D. Durham, President and CEO of ADA-ES, commented, "To date, we have installed or are in the process of installing 45 ACI systems, including the nine contracts secured thus far in 2009. In October, the EPA entered into a consent decree under which it agreed to adopt Maximum Achievable Control Technology ("MACT")-based regulations for hazardous air pollutants including mercury from coal-fired boilers, stating that a final rule should be in place by November 2011, with full implementation by 2014. These regulations, along with other expected EPA MACT regulations for industrial boilers and cement kilns and a three pollutant bill including mercury currently under Senate review, should notably expand the markets for ACI systems and activated carbon. In the meantime, we anticipate steady sales of ACI systems for the next few quarters stemming from regulations in 19 states and several Canadian provinces and new power plants being constructed." Activated Carbon Business Update ADA Carbon Solutions ("ADA-CS"), the Company's joint venture with Energy Capital Partners I, LP and its affiliated funds ("ECP"), is progressing on its new activated carbon ("AC") processing and production facilities in Louisiana. Construction of the AC manufacturing plant in Red River Parish, LA appears to be on budget and on schedule to begin operation in the spring of 2010. Funding of construction, which approximates $200 million to date, continues with interim financing by ECP. The Company, ADA-CS, and ECP are working on securing permanent debt to replace the interim financing, and once in place, the Company expects to own 25% of the first production line with rights to own up to 50% of additional lines that it believes will be necessary to meet demand generated by a Federal mercury control regulation. The Company received very promising news on $245 million of debt financing for the plant last Thursday and expects to be able to provide additional information regarding this financing opportunity later this week.

ADA-CS has signed AC sales contracts for one-third of the nameplate capacity of the Red River Parish plant for the first five years of production, and is competing on a number of bids submitted this year. The Company believes that several of these will result in additional supply contracts before the end of the year.

Refined Coal Update Dr. Durham continued, "With regard to our Refined Coal product, Cyclean, marketed through our Clean Coal joint venture with NexGen, the IRS has yet to issue the anticipated guidance as to the specifics concerning how the emissions reductions are to be measured and certified to demonstrate the continuous compliance necessary to qualify for the Tax Credits. The uncertainty created by these delays has reduced the number of systems that could be placed in service before year end. As a result, our current goal is to get two placed in service before the end of the year. We began construction of the equipment in July, so that we could meet this deadline. These systems could generate $3 million to $6 million in operating income for the Company each year for a 10-year period if the deadline is met. These installations would also trigger $4 million in payments to the Company from NexGen to maintain its 50% ownership of the joint venture." Concluding Remarks Dr. Durham concluded, "We look forward to launching ADA-CS' AC manufacturing facility in spring 2010. We will continue to fine-tune our business strategy, and focus on positioning ADA-ES as a market leader in clean coal technology. We remain enthusiastic about our prospects for long-term growth." Conference Call Management will conduct a conference call focusing on the financial results and recent developments at 10:00 AM ET on Monday, November 16, 2009. Interested parties may participate in the call by dialing 706-679-3200. Please call in 10 minutes before the call is scheduled to begin, and ask for the ADA call (conference ID # 33504955). The conference call will also be webcast live via the Investor Information section of ADA's website at www.adaes.com. To listen to the live call please go the website at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the website.

About ADA-ES ADA-ES is a leader in clean coal technology and the associated specialty chemicals. The Company develops and implements proprietary environmental technology and specialty chemicals that enable coal-fueled power plants to enhance existing air pollution control equipment, maximize capacity and improve operating efficiencies. Through its largest segment, Mercury Emission Control, ADA-ES supplies activated carbon injection systems, mercury measurement instrumentation, and related services. To meet the needs of the power industry for mercury control, ADA-CS, the Company's joint venture with ECP, is developing state-of-the-art facilities to produce AC with the first plant projected to come on-line in 2010. Additionally, the Company is developing technologies for power plants to address issues related to the emissions of carbon dioxide.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]

Discussions:


	Be the first to post a comment on this page!

TMCnet

+ Add to the Discussion

Bookmark mobile.TMCnet.com on your mobile phone now to stay on top of the latest tech news.

Featured White Papers

Power and Cooling Capacity Management for Data Centers

Deploying High-Density Zones in a Low-Density Data Center

Selecting an Industry-Standard Metric for Data Center Efficiency

view all white papers…

The World's Largest Communications And Technology Community

Technology Marketing Corporation,
800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-866-3326
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.

» About » Contact » Advertise